Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11763036 | 0.77 | CA12 (0.47) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL14345149 | 0.77 | — | — | |
| SCHEMBL4981455 | 0.76 | CA12 (0.56) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL10742927 | 0.76 | CA12 (0.61) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL3422335 | 0.76 | CA12 (0.50) | CA12CA1CA2CA9CYP2D6 | |
| Hydrochloric Acid SCHEMBL28618348 | 0.76 | CA12 (0.45) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL14344938 | 0.75 | HTT (0.36) | ALDH1A1HTTLMNA | |
| Hydrochloric Acid SCHEMBL28247897 | 0.74 | CYP2D6 (0.49) | CA12CA1CA2CA9CYP2D6 | |
| Iodide SCHEMBL28247499 | 0.74 | CYP2D6 (0.49) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL28247895 | 0.74 | CYP2D6 (0.49) | CA12CA1CA2CA9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190145981-A1 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | SPHINGOTEC THERAPEUTICS GMBH (DE) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190145981-A1 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | DPP3, DPP4, DPP7 | CA12 258/4885CA1 450/4885CA2 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.